Huntington disease
Drug research and approvals for huntington disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 41 studies of huntington disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 34 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 41
- Trials authorized in Canada: 34
- FDA orphan approvals: 2
- EU medicines: 0
- Pridopidine Phase 3 Study in Huntington's DiseaseNCT07609108 · Phase 3 · Prilenia · starts Jul 1, 2026
- A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's DiseaseNCT07536061 · Phase 1 · Sarepta Therapeutics, Inc. · starts May 12, 2026
- Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's DiseaseNCT07513844 · Not applicable · First Affiliated Hospital of Fujian Medical University · starts Apr 20, 2026
- Safety and Tolerability Study of Human Neural Stem Cells for Huntington's DiseaseNCT07451613 · Phase 1 / Phase 2 · Leslie Thompson · starts Apr 6, 2026
- Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's DiseaseNCT07378644 · Phase 2 / Phase 3 · Skyhawk Therapeutics, Inc. · starts Jan 6, 2026
- A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's DiseaseNCT07326709 · Phase 3 · Novartis Pharmaceuticals · starts Mar 24, 2026
- Feasibility and Acceptability of an LLM-based Chatbot for Family Caregivers: Evaluation StudyNCT07280650 · Not applicable · University of Michigan · starts Sep 2, 2026
- Evaluation of Three Tests to Assess Social Cognition in Huntington DiseaseNCT07253038 · Not reported · Region Skane · starts Dec 1, 2025
- Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic PathologyNCT07136844 · Not applicable · Centre Hospitalier Universitaire de Liege · starts Mar 29, 2024
Approved 1
- TetrabenazineSynaptic vesicular amine transporter inhibitor
Phase 3 12
- PridopidineDopamine D2 receptor modulator
- Creatine
- TominersenHuntingtin mRNA antisense inhibitor
- Latrepirdine
- Dalzanemdor
- ValbenazineSynaptic vesicular amine transporter inhibitor
- UbidecarenoneSupplement
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- RiluzoleSodium channel alpha subunit blocker
- TiaprideDopamine D3 receptor antagonist
- Resveratrol
Phase 2 12 of 23
- MardepodectPhosphodiesterase 10A inhibitor
- MinocyclineBacterial 70S ribosome inhibitor
- TriheptanoinSupplement
- BupropionDopamine transporter inhibitor
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- FenofibratePeroxisome proliferator-activated receptor alpha agonist
- MemantineGlutamate [NMDA] receptor negative allosteric modulator
- Phenylbutanoic acidGlutamine sequestering agent
- NeflamapimodMAP kinase p38 alpha inhibitor
- MavoglurantMetabotropic glutamate receptor 5 antagonist
- SRX246Vasopressin V1a receptor antagonist
Phase 1 or earlier 12
- PBF-999Adenosine A2a receptor antagonist
- GSK-356278
- Lexanersen
- HaloperidolSerotonin 2a (5-HT2a) receptor antagonist
- NilotinibTyrosine-protein kinase ABL inhibitor
- SertralineSerotonin transporter inhibitor
- RisperidoneSerotonin 2a (5-HT2a) receptor antagonist
- UrsodiolBile acid receptor FXR agonist
- IdebenoneAntioxidant and mitochondrial electron carrier
- RolipramPhosphodiesterase 4 inhibitor
- Rovanersen sodium
- Votoplam
How its trials ended
262 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 46 whose ending is known, 28% met their primary endpoint, 17% missed it and 54% stopped early.
- Completed, result not reported12849%
- Ongoing5019%
- Status unknown3815%
- Met its primary endpoint135%
- Stopped: lack of efficacy93%
- Stopped: other or unclear93%
- Missed its primary endpoint83%
- Stopped: sponsor or business decision31%
- Stopped: safety21%
- Stopped: enrollment or feasibility21%
| Jun 3, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine in participants with Huntington’s disease (HD)Pridopidine (PL101) | Prilenia Therapeutics B.V. | Pending |
| May 5, 2026 | A phase 2/3 randomized, double blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety and efficacy of SKY-0515 in participants…SKY-0515 | Skyhawk Therapeutics, Inc. | Ongoing |
| Feb 3, 2026 | A randomized, placebo-controlled, double-blind phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s…Votoplam (PTC518, HTT227) | Novartis Pharmaceuticals | Ongoing |
| Oct 17, 2025 | A phase I, 2-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of intrathecally administered…RG6496 (RO7764733) | Roche | Ongoing |
| Jul 18, 2024 | A randomized, double-blind, placebo-controlled study, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intrathecally…ALN-HTT02 | Alnylam Pharmaceuticals | Ongoing |
| Jul 2, 2024 | A phase 2b, double-blind, randomized extension study to evaluate the long-term safety and efficacy of votoplam in participants with Huntington's diseaseVotoplam (HTT227, PTC518) | Novartis Pharmaceuticals | Ongoing |
| Dec 18, 2023 | Long-term study to evaluate safety and tolerability of valbenazine in patients with chorea associated with Huntington disease in canadaValbenazine | Neurocrine Biosciences | Ongoing |
| Feb 16, 2023 | A phase 3, multicenter, open-label safety study to evaluate the long-term safety and tolerability of SAGE-718 in participants with Huntington's diseaseSAGE-718 | Sage Therapeutics | Closed |
| Dec 15, 2022 | A phase II, randomized, double-blind, placebo-controlled, dose-finding study to investigate the safety, biomarkers, and efficacy of tominersen in individuals…Tominersen (RO7234292) | Roche | Ongoing |
| Nov 3, 2022 | A phase 2a, randomized, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of PTC518 in subjects with Huntington's diseasePTC518 | PTC Therapeutics | Closed |
| Apr 30, 2024 | IngrezzaTreatment of adults with chorea associated with Huntington's disease | Neurocrine Biosciences Inc. | Approved |
| Aug 18, 2023 | IngrezzaTreatment of adults with chorea associated with Huntington's disease | Neurocrine Biosciences Inc. | Approved |
| Feb 11, 2019 | 2,4-dinitrophenolTreatment of Huntington disease | Mitochon Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA